



## PRESS RELEASE

**ANANDA Scientific and the David Geffen School of Medicine, UCLA, Announce Commencement of a clinical trial evaluating Nantheia™ ATL5 for Smoking Cessation.**

---

[businesswire.com/news/home/20241022571870/en](https://www.businesswire.com/news/home/20241022571870/en)

October 22, 2024



Edythe London, Ph.D.



Sohail Zaidi  
CEO, Ananda Scientific

GREENWOOD VILLAGE, Colo. & LOS ANGELES, CA--(BUSINESS WIRE)-- [ANANDA Scientific Inc.](#), a research focused bio-pharmaceutical company and the Semel Institute for Neuroscience at Geffen School of Medicine UCLA today announced the commencement of a clinical trial evaluating **Nantheia™ ATL5**, an investigational drug combining cannabidiol (CBD) with **ANANDA's** proprietary delivery technology to evaluate the efficacy of cannabidiol for smoking cessation. ([Clinical Trials.gov Identifier:NCT06218056](#))

This trial is being led by principal investigator [Edythe London, Ph.D.](#), Distinguished Professor of Psychiatry and Biobehavioral Sciences as well as Molecular and Medicinal Pharmacology at the Semel Institute, Geffen School of Medicine UCLA. Funding for this trial is through a grant provided by the Center for Medicinal Cannabis Research.

“We are excited to have commenced this clinical trial with **Nantheia™ ATL5** in collaboration with Ananda,” said Dr. London. “Cigarette smoking continues to be a major health issue worldwide, and we are keen to develop new evidence-based approaches for reducing cigarette smoking and nicotine addiction.”

“**ANANDA** is again delighted to be working with Dr. London and the Geffen School of Medicine on



## PRESS RELEASE

this important trial with our investigational drug, **Nantheia™ ATL5**,” said [Sohail R. Zaidi](#), **ANANDA’s** Chief Executive Officer (CEO). “This clinical study is an important component of our clinical development efforts to develop non-addictive therapies to address significant health issues.”

In this randomized, double-blind, placebo-controlled study, participants will receive **Nantheia™ ATL5** (800mg CBD) or placebo daily for 8 weeks. The primary endpoint will be reduction in cigarette use from baseline. Secondary endpoints will assess the impact of nicotine withdrawal and its impact on general anxiety and mood states.

### ABOUT NANTHEIA™ ATL5

**Nantheia™ ATL5** is an investigational drug that combines cannabidiol with **ANANDA’s** proprietary **Liquid Structure™** delivery technology. Pre-clinical and initial clinical studies show that **ANANDA’s Liquid Structure™** delivery Technology, (licensed from [Lyotropic Delivery Systems \(LDS\) Ltd](#) in Jerusalem, Israel) enhances the effectiveness, consistent absorption and stability of cannabidiol. **Nantheia™ ATL5** is an oral product with 100mg of cannabidiol per softgel capsule.

### ABOUT ANANDA SCIENTIFIC

**ANANDA Scientific** is a leading research-focused biopharmaceutical company focused on developing life-changing medicines to transform neuropsychiatric health. The company is currently conducting high-caliber clinical studies evaluating **Nantheia™** for therapeutic indications such as PTSD, Pain, Anxiety, Opioid Use Disorder and Smoking Cessation. The company’s patented delivery technology makes cannabinoids and plant-derived compounds highly bioavailable, water-soluble, and shelf-life stable. **ANANDA Scientific** is dedicated to producing effective, premium pharmaceutical products that enhance patients' lives.

This press release includes forward-looking statements that involve risks and uncertainties. Such statements are based on current assumptions and expectations, which may change over time.

### Contacts

ANANDA Scientific Media Relations

[Christopher Moore](#)

813 326 4265

[chris.moore@anandascientific.com](mailto:chris.moore@anandascientific.com)